Physician profile
Todd M Mcniff
NPI 1134370679
$86,119.00
in general payments reported to CMS, 2019-2025
13 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.20 · 2022: $15K · 2023: $15K · 2024: $22K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $4,773 · Travel and Lodging: $2,055 · Education: $67.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,350.00 |
| Food and Beverage | $4,772.69 |
| Travel and Lodging | $2,055.42 |
| Education | $67.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $85,067.02 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $603.88 | 2021-2025 | Yeztugo, Biktarvy |
| Lundbeck LLC | $118.72 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $83.59 | 2025 | Rexulti |
| Novo Nordisk INC | $58.72 | 2025 | Ozempic, Rybelsus, Wegovy |
| Intra-Sana Laboratories | $35.56 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Seqirus USA INC | $30.22 | 2022-2024 | Flucelvax, Fluad |
| Antares Pharma, INC. | $25.62 | 2025 | Xyosted |
| Lilly USA, LLC | $22.25 | 2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $21.81 | 2025 | Pifeltro |
| Amgen INC. | $19.99 | 2025 | Repatha |
| Abbvie INC. | $18.29 | 2025 | |
| Napo Pharmaceuticals INC | $13.33 | 2025 | Mytesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Mcniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.